Condition
Endogenous Cushing's Syndrome
Total Trials
4
Recruiting
0
Active
1
Completed
3
Success Rate
100.0%+13% vs avg
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Clinical Risk Assessment
Based on trial outcomes
Low Risk
Score: 5/100
Termination Rate
0.0%
0 terminated out of 4 trials
Success Rate
100.0%
+13.5% vs benchmark
Late-Stage Pipeline
50%
2 trials in Phase 3/4
Results Transparency
67%
2 of 3 completed with results
Key Signals
2 with results100% success
Data Visualizations
Phase Distribution
2Total
P 3 (2)
Trial Status
Completed3
Active Not Recruiting1
Trial Success Rate
100.0%
Benchmark: 86.5%
Based on 3 completed trials
Clinical Trials (4)
Showing 4 of 4 trials
NCT05382156Active Not RecruitingPrimary
Non-interventional Study on Osilodrostat in Patients With Endogenous Cushing's Syndrome
NCT03880513CompletedPrimary
Cardiovascular Status in Patients With Endogenous Cortisol Excess (Cushing's Syndrome)
NCT03277690Phase 3CompletedPrimary
A Study to Assess the Safety and Efficacy of Levoketoconazole in the Treatment of Endogenous Cushing's Syndrome.
NCT01838551Phase 3CompletedPrimary
Treatment for Endogenous Cushing's Syndrome
Showing all 4 trials